SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001127602-24-015369
Filing Date
2024-05-15
Accepted
2024-05-15 07:14:54
Documents
1
Period of Report
2024-05-13

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form4.html 4  
1 PRIMARY DOCUMENT form4.xml 4 3260
  Complete submission text file 0001127602-24-015369.txt   4769
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O BIOCRYST PHARMACEUTICALS, INC. 4505 EMPEROR BLVD, SUITE 200 DURHAM NC 27703
Business Address
Galson Steven K (Reporting) CIK: 0001495328 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-23186 | Film No.: 24947128